<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02904603</url>
  </required_header>
  <id_info>
    <org_study_id>IM-HC-1516</org_study_id>
    <nct_id>NCT02904603</nct_id>
  </id_info>
  <brief_title>Immune Monitoring of Hepatitis C Under DAA Therapy</brief_title>
  <acronym>IMHC</acronym>
  <official_title>Prospective Monitoring of Immune Parameters in Patients With Hepatitis C Under Treatment With Direct Acting Antivirals</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Regensburg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Regensburg</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Direct acting antivirals offer a new opportunity to monitor the immune response in Hepatitis
      C infection. In this study cytokine markers will be measured during therapy up to time point
      SVR 12 an correlated to clinical Parameters and regular laboratory findings.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Anticipated">January 2017</completion_date>
  <primary_completion_date type="Anticipated">November 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change of IP10 and related cytokines during treatment (ng/ml)</measure>
    <time_frame>24 weeks (observation time under and after DAA therapy)</time_frame>
    <description>Screening for Biomarkers under DAA Therapy until timepoint SVR 12 (12 weeks treatment plus control 12 weeks after end of Treatment = 24 weeks)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>SVR 12</measure>
    <time_frame>24 weeks (12 weeks treatment plus control 12 weeks after end of treatment)</time_frame>
    <description>Eradication of HCV RNA 12 weeks after end of Treatment (Treatment 12 weeks)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of inflammatory markers (ferritin ng/ml, CRP mg/l, PCT ng/ml) during treatment</measure>
    <time_frame>24 weeks (observation time under DAA therapy)</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Hepatitis C</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum probes
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients under DAA therapy &gt; 18 years monocentral.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  written consent, age, HCV-RNA positive, DAA therapy

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kilian Weigand</last_name>
    <role>Study Chair</role>
    <affiliation>Uiversity of Regensburg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Georg Peschel</last_name>
    <phone>00499419447012</phone>
    <email>georg.peschel@ukr.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kilian Weigand</last_name>
    <phone>00499419447012</phone>
    <email>kilian.weigand@ukr.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Regensburg</name>
      <address>
        <city>Regensburg</city>
        <zip>93047</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Georg Peschel</last_name>
      <phone>00499419447012</phone>
      <email>georg.peschel@ukr.de</email>
    </contact>
    <contact_backup>
      <last_name>Kilian Weigand</last_name>
      <phone>00499419447012</phone>
      <email>kilian.weigand@ukr.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 6, 2016</study_first_submitted>
  <study_first_submitted_qc>September 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2016</study_first_posted>
  <last_update_submitted>September 20, 2016</last_update_submitted>
  <last_update_submitted_qc>September 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Regensburg</investigator_affiliation>
    <investigator_full_name>Dr. Georg Peschel</investigator_full_name>
    <investigator_title>Dr. med.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

